IN2014DN04587A - - Google Patents

Info

Publication number
IN2014DN04587A
IN2014DN04587A IN4587DEN2014A IN2014DN04587A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A IN 4587DEN2014 A IN4587DEN2014 A IN 4587DEN2014A IN 2014DN04587 A IN2014DN04587 A IN 2014DN04587A
Authority
IN
India
Prior art keywords
compounds
methods
administering
acceptable salts
compositions containing
Prior art date
Application number
Inventor
Chang H Ahn
Won J Choi
Young B Lee
Lak S Jeong
Sang K Lee
Original Assignee
Rexahn Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rexahn Corp filed Critical Rexahn Corp
Publication of IN2014DN04587A publication Critical patent/IN2014DN04587A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention relates to nucleoside derivatives represented by general formulas (I) and (II), their synthetic methods and their pharmacologically acceptable salts thereof, and compositions containing such compounds. Methods for treating hyperproliferative disorders by administering the compounds are also included.
IN4587DEN2014 2004-04-01 2005-04-01 IN2014DN04587A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55814104P 2004-04-01 2004-04-01
PCT/US2005/011313 WO2005097757A2 (en) 2004-04-01 2005-04-01 Nucleoside derivatives and therapeutic use thereof

Publications (1)

Publication Number Publication Date
IN2014DN04587A true IN2014DN04587A (en) 2015-07-10

Family

ID=34979006

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4587DEN2014 IN2014DN04587A (en) 2004-04-01 2005-04-01

Country Status (15)

Country Link
US (1) US7405214B2 (en)
EP (1) EP1732902B1 (en)
JP (2) JP5001832B2 (en)
KR (1) KR100926596B1 (en)
CN (2) CN102091072A (en)
AT (1) ATE453628T1 (en)
AU (1) AU2005230676B2 (en)
BR (1) BRPI0509553B8 (en)
CA (1) CA2562965C (en)
DE (1) DE602005018620D1 (en)
ES (1) ES2334803T3 (en)
IN (1) IN2014DN04587A (en)
MX (1) MXPA06011141A (en)
PL (1) PL1732902T3 (en)
WO (1) WO2005097757A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9315534B2 (en) * 2007-08-10 2016-04-19 Board Of Regents Of The University Of Nebraska Radiologic agents for monitoring alzheimer's disease progression and Evaluating a Response to Therapy and processes for the preparation of such agents
WO2011079245A1 (en) * 2009-12-23 2011-06-30 Board Of Regents Of The University Of Nebraska Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
ES2678085T3 (en) 2013-03-15 2018-08-08 Rexahn Pharmaceuticals, Inc. Process for the preparation of 4-amino-1 - ((1S, 4R, 5S) -2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl) -1H-pyrimidin-2-one
US9782410B2 (en) * 2015-06-09 2017-10-10 Rexahn Pharmaceuticals, Inc. Fluorocyclopentenylcytosine methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6187674A (en) * 1984-10-06 1986-05-06 Yoshitomi Pharmaceut Ind Ltd Novel nucleoside containing cyclopentene ring
US4975434A (en) * 1986-05-27 1990-12-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antiviral and anticancer cyclopentenyl cytosine
DK1411954T3 (en) 2000-10-18 2011-03-14 Pharmasset Inc Modified nucleosides to treat viral infections and abnormal cellular proliferation
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds

Also Published As

Publication number Publication date
JP2007531736A (en) 2007-11-08
CN1980898B (en) 2011-01-12
CA2562965A1 (en) 2005-10-20
DE602005018620D1 (en) 2010-02-11
CA2562965C (en) 2013-10-29
BRPI0509553A (en) 2007-09-18
JP2012107072A (en) 2012-06-07
WO2005097757A3 (en) 2005-12-08
KR100926596B1 (en) 2009-11-11
WO2005097757A2 (en) 2005-10-20
EP1732902A2 (en) 2006-12-20
BRPI0509553B8 (en) 2021-05-25
EP1732902B1 (en) 2009-12-30
US7405214B2 (en) 2008-07-29
CN1980898A (en) 2007-06-13
AU2005230676B2 (en) 2010-10-07
JP5001832B2 (en) 2012-08-15
MXPA06011141A (en) 2007-08-14
BRPI0509553B1 (en) 2019-06-18
ATE453628T1 (en) 2010-01-15
PL1732902T3 (en) 2010-06-30
CN102091072A (en) 2011-06-15
AU2005230676A1 (en) 2005-10-20
KR20070012685A (en) 2007-01-26
US20050222185A1 (en) 2005-10-06
ES2334803T3 (en) 2010-03-16

Similar Documents

Publication Publication Date Title
MX2009003958A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof.
MXPA06009475A (en) Quinazoline derivatives and therapeutic use thereof.
TW200612936A (en) Indole derivatives
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
TW200510301A (en) Novel compounds
TW200600506A (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.
MX2007007027A (en) Piperazinyl pyridine derivatives as anti-obesity agents.
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
UA87856C2 (en) Alkynyl derivatives as modulators of metatropic glutamate receptors
ATE530519T1 (en) CYCLOBUTYLAMINE DERIVATIVES
TW200407305A (en) Novel compounds
SE0202241D0 (en) Novel Compounds
DE602006014579D1 (en) HETEROALKYL-TIED PYRIMIDINE DERIVATIVES
MX2010005649A (en) Novel compounds as cannabinoid receptor ligands and uses thereof.
ATE430744T1 (en) THIAZOLYLPIPERIDINE DERIVATIVES USEFUL AS H3 RECEPTOR MODULATORS
TW200626158A (en) Naphthaline derivatives
MX2010013682A (en) Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders.
MX2007011847A (en) Pyrimidindione derivatives as prokineticin 2 receptor antagonists.
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
MX2009000169A (en) Purinone derivatives as hm74a agonists.
TW200637817A (en) 5-aminoindole derivatives
MX2010001486A (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists.
IS8377A (en) Arylindenopyridine and arylindenopyrimidine and their use as antagonists of the A2A adenosine receptor